Header cover image

French (CAC) Biotech Industry Analysis

UpdatedMay 18, 2024
DataAggregated Company Financials
Companies27
  • 7D1.9%
  • 3M6.5%
  • 1Y-18.2%
  • YTDn/a

In the last week, the Biotech industry is up 3.2%, with Valneva up 25%. However, the industry is down 19% over the past year. Earnings are forecast to grow by 24% annually.

Industry Valuation and Performance

Has the French Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 18 May 2024€3.3b€502.3m-€592,424,218.4827.9x-5.6x6.5x
Mon, 15 Apr 2024€3.3b€515.7m-€629,475,775.7328.4x-5.2x6.3x
Wed, 13 Mar 2024€3.1b€567.7m-€646,653,407.2521.5x-4.8x5.5x
Fri, 09 Feb 2024€3.0b€558.9m-€674,927,750.1822.4x-4.4x5.4x
Sun, 07 Jan 2024€3.2b€594.3m-€683,335,361.0023.1x-4.7x5.4x
Tue, 05 Dec 2023€3.2b€594.7m-€685,255,395.0021.7x-4.6x5.3x
Thu, 02 Nov 2023€3.1b€803.5m-€567,784,769.0021x-5.5x3.9x
Sat, 30 Sep 2023€3.3b€827.5m-€579,145,511.0014.2x-5.8x4x
Mon, 28 Aug 2023€3.7b€818.2m-€727,289,207.0024.1x-5.1x4.5x
Wed, 26 Jul 2023€3.8b€817.5m-€734,744,130.0024.5x-5.2x4.6x
Fri, 23 Jun 2023€3.9b€819.7m-€742,987,860.0025.3x-5.3x4.8x
Sun, 21 May 2023€3.8b€831.2m-€761,674,629.0026.1x-4.9x4.5x
Tue, 18 Apr 2023€3.5b€878.2m-€769,875,315.0031.6x-4.5x4x
Thu, 16 Mar 2023€3.3b€1.0b-€470,273,558.009.7x-7x3.2x
Sat, 11 Feb 2023€3.7b€1.0b-€457,392,283.0011.5x-8.1x3.5x
Mon, 09 Jan 2023€3.7b€1.0b-€455,883,646.0012.1x-8x3.5x
Wed, 07 Dec 2022€3.5b€1.0b-€457,899,023.0012.6x-7.5x3.3x
Fri, 04 Nov 2022€3.6b€914.4m-€705,389,452.0016.5x-5.1x3.9x
Sun, 02 Oct 2022€3.2b€923.3m-€677,984,751.0031x-4.7x3.5x
Tue, 30 Aug 2022€4.4b€930.8m-€751,667,630.00115x-5.8x4.7x
Thu, 28 Jul 2022€4.4b€985.5m-€688,213,309.00120.9x-6.3x4.4x
Sat, 25 Jun 2022€4.7b€993.1m-€693,029,894.00126x-6.7x4.7x
Mon, 23 May 2022€4.7b€991.3m-€692,391,260.00134.4x-6.8x4.8x
Wed, 20 Apr 2022€5.1b€1.2b-€489,700,261.003x-10.5x4.2x
Fri, 18 Mar 2022€5.5b€950.8m-€648,046,770.0017.4x-8.5x5.8x
Sun, 13 Feb 2022€5.4b€929.8m-€675,308,815.003x-7.9x5.8x
Tue, 11 Jan 2022€6.1b€931.7m-€678,654,271.003.2x-9x6.5x
Thu, 09 Dec 2021€6.9b€923.1m-€680,995,918.002.7x-10.1x7.4x
Sat, 06 Nov 2021€6.5b€921.3m-€672,182,761.002.3x-9.7x7.1x
Mon, 04 Oct 2021€6.8b€902.4m-€738,666,719.002.6x-9.2x7.5x
Wed, 01 Sep 2021€7.7b€899.6m-€600,532,159.122.9x-12.8x8.5x
Thu, 08 Jul 2021€6.5b€899.6m-€600,532,159.122.8x-10.8x7.2x
Price to Earnings Ratio

-11.8x


Total Market Cap: €6.7bTotal Earnings: -€570,006,611.92Total Revenue: €882.0mTotal Market Cap vs Earnings and Revenue0%0%0%
French Biotech Industry Price to Earnings3Y Average -7x202220232024
Current Industry PE
  • Investors are optimistic on the French Biotechnology industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 5.2x is lower than the industry's current PS ratio of 6.6x.
Past Earnings Growth
  • Losses for companies in the Biotechnology industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have declined 17% per year.
  • This means that the cost of doing business could be reducing since sales have declined but losses haven't fallen much further.

Industry Comparison

How does French Biotech compare with similar industries?

FR Market-0.42%
Healthcare-2.18%
Biotech1.93%
Biotech1.93%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VLA Valneva€4.1021.9%
+€102.1m
-27.9%PS3.7x
IVA Inventiva€3.6010.4%
+€19.0m
36.1%PS8.1x
NANO Nanobiotix€6.776.2%
+€18.6m
50.7%PS8.8x
OSE OSE Immunotherapeutics€7.419.8%
+€14.2m
96.0%PS71.8x
ADOC Adocia€9.5510.7%
+€14.2m
167.5%PS22.7x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

GNRO

€1.85

GeNeuro

7D

26.3%

1Y

-1.3%

NANO

€6.77

Nanobiotix

7D

6.2%

1Y

50.7%

ALNOV

€0.72

Novacyt

7D

-8.5%

1Y

50.5%

MAAT

€8.22

MaaT Pharma

7D

-12.0%

1Y

1.5%

ADOC

€9.55

Adocia

7D

10.7%

1Y

167.5%

TNG

€1.33

Transgene

7D

-1.6%

1Y

-24.5%

IVA

€3.60

Inventiva

7D

10.4%

1Y

36.1%

DBV

€1.27

DBV Technologies

7D

4.8%

1Y

-63.1%

ALMDP

€0.97

Medesis Pharma

7D

-30.2%

1Y

-52.7%

OSE

€7.41

OSE Immunotherapeutics

7D

9.8%

1Y

96.0%

ABVX

€12.92

ABIVAX Société Anonyme

7D

-3.4%

1Y

-29.7%

ALSEN

€0.71

Sensorion

7D

-1.4%

1Y

153.6%

ALCLS

€2.65

Cellectis

7D

-6.7%

1Y

57.6%

ALVAL

€4.13

Valbiotis

7D

-10.1%

1Y

12.4%

IPH

€2.41

Innate Pharma

7D

6.6%

1Y

-12.2%